Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Advanced or Metastatic Solid Malignancies
Clinical Trial
NCT04887870Last updated: 12/4/2025
MRTX
Mirati Therapeutics, Inc.